IgA nephropathy
Clinical trials for IgA nephropathy explained in plain language.
Never miss a new study
Get alerted when new IgA nephropathy trials appear
Sign up with your email to follow new studies for IgA nephropathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a transplant drug tame stubborn kidney disease?
Disease control Not yet recruitingThis trial asks whether mycophenolate mofetil (MMF) can help people with IgA nephropathy whose disease hasn't improved with standard care. About 104 adults with biopsy-confirmed refractory IgA nephropathy will be randomly assigned to take either MMF or the steroid prednisolone fo…
Matched conditions: IGA NEPHROPATHY
Phase 2 • Sponsor: Shaheed Suhrawardy Medical College and Hospital • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new injection slow kidney disease in children?
Disease control Not yet recruitingThis phase 3 trial is testing whether sibeprenlimab, an investigational drug given as an injection every 4 weeks, can help children and adolescents with IgA nephropathy. The study includes about 24 participants aged 2 to 17 with biopsy-confirmed disease. The main goal is to see i…
Matched conditions: IGA NEPHROPATHY
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug BHV-1400 aims to protect kidneys in IgA nephropathy
Disease control Not yet recruitingThis Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…
Matched conditions: IGA NEPHROPATHY
Phase 3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kidney disease: experimental drug targets protein leak
Disease control Not yet recruitingThis early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…
Matched conditions: IGA NEPHROPATHY
Phase 2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New injection aims to tame kidney disease
Disease control Not yet recruitingThis Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or…
Matched conditions: IGA NEPHROPATHY
Phase 2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
New study to track how kidney disease drugs work in real life
Knowledge-focused Not yet recruitingThis study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC